The University of Western Australia, 35 Stirling Hwy, Crawley, WA, 6009, Australia.
J Foot Ankle Res. 2022 Apr 11;15(1):27. doi: 10.1186/s13047-022-00535-6.
There is limited evidence in the literature to describe an analgesic protocol that takes into consideration the extent of foot and ankle surgery. The aim of this study was to develop a guide for acute postoperative pain management for podiatric surgery in Australia, and to identify opportunities to improve the current list of scheduled medicines available to podiatric surgeons.
A Delphi method involving 3 survey rounds was employed for this study. Twelve expert panellists in the field of podiatric surgery and anaesthesiology were invited to participate, and 10 panellists remained by the end of the study. Round 1 involved 15 open-ended questions. These answers formed the basis of the 55 statements that were developed for the following 2 survey rounds, where panellists rated the appropriateness of each statement on a 9-point Likert scale. The third survey round was an opportunity for panellists to revise their answers to each statement in light of the majority response.
For mild acute postoperative pain, non-opioid oral analgesics were recommended as an appropriate management option. For moderate and severe acute postoperative pain, both non-opioid and opioid products were found to be appropriate by the majority. It was agreed that oral opioids be reserved for breakthrough pain at all severity levels. All other statements in the Delphi study pertaining to drug hypersensitivities or allergies, stratification of pain management, opioid prescription concerns, and access to pain medications were accepted as appropriate by the majority of panellists.
The agreed approach to acute postoperative pain management for podiatric surgeons in Australia was with a stepwise approach, utilising multimodal therapy, and reserving oral opioids for breakthrough pain. Additionally, there was consensus for podiatric surgeons in Australia to have wider access to alternative analgesics and anti-emetics that have similar or improved efficacies with better safety profiles.
文献中仅有有限的证据描述了一种考虑到足踝手术范围的镇痛方案。本研究旨在为澳大利亚足病手术的急性术后疼痛管理制定指南,并确定改善足病外科医生目前可用的预定药物清单的机会。
本研究采用德尔菲法,共进行了 3 轮调查。邀请了 12 名足病手术和麻醉领域的专家小组参加,研究结束时仍有 10 名小组成员。第 1 轮涉及 15 个开放式问题。这些答案构成了接下来 2 轮调查中 55 个陈述的基础,小组成员在 9 点 Likert 量表上对每个陈述的适当性进行了评分。第 3 轮调查为小组成员提供了根据多数人的意见修改对每个陈述的答案的机会。
对于轻度急性术后疼痛,非阿片类口服镇痛药被推荐为一种适当的治疗选择。对于中度和重度急性术后疼痛,大多数人认为非阿片类和阿片类药物都是合适的。一致认为,在所有严重程度的疼痛中,都应将口服阿片类药物保留用于突破性疼痛。德尔菲研究中关于药物过敏或过敏、疼痛管理分层、阿片类药物处方问题以及获得疼痛药物的所有其他陈述,都被大多数小组成员认为是合适的。
澳大利亚足病外科医生急性术后疼痛管理的一致方法是采用逐步方法,利用多模式治疗,并将口服阿片类药物保留用于突破性疼痛。此外,澳大利亚的足病外科医生还需要更广泛地获得具有相似或改善疗效且安全性更好的替代镇痛剂和止吐药。